PKI-06.29.2014-10Q Document
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________________ 
FORM 10-Q
_______________________________________ 
(Mark One)
ý
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 29, 2014
or
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ____________ to ____________
Commission File Number 001-5075
_______________________________________ 
PerkinElmer, Inc.
(Exact name of Registrant as specified in its Charter)
_______________________________________  
Massachusetts
 
04-2052042
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
940 Winter Street
Waltham, Massachusetts 02451
(Address of principal executive offices) (Zip code)
(781) 663-6900
(Registrant’s telephone number, including area code)
_______________________________________ 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ý    No  ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ý    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. 
Large accelerated filer
 
ý
Accelerated filer
 
¨
 
 
 
 
Non-accelerated filer
 
¨ (Do not check if a smaller reporting company)
Smaller reporting company
 
¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  ý
As of July 31, 2014, there were outstanding 112,919,479 shares of common stock, $1 par value per share.


Table of Contents

TABLE OF CONTENTS
 
 
 
Page
PART I. FINANCIAL INFORMATION
 
 
 
Item 1.
 
 
 
 
 
 
 
 
Item 2.
 
 
 
 
 
 
 
 
 
 
 
Item 3.
 
 
 
Item 4.
 
 
PART II. OTHER INFORMATION
 
 
 
 
Item 1.
 
 
 
Item 1A.
 
 
 
Item 2.
 
 
 
Item 6.
 
 
 
 



2

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1.
Unaudited Financial Statements

PERKINELMER, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited) 
 
Three Months Ended
 
Six Months Ended
 
June 29,
2014
 
June 30,
2013
 
June 29,
2014
 
June 30,
2013
 
(In thousands, except per share data)
Product revenue
$
381,609

 
$
374,024

 
$
747,093

 
$
720,643

Service revenue
174,561

 
166,649

 
339,687

 
322,973

Total revenue
556,170

 
540,673

 
1,086,780

 
1,043,616

Cost of product revenue
201,649

 
195,748

 
390,933

 
376,870

Cost of service revenue
106,537

 
103,263

 
212,150

 
200,642

Total cost of revenue
308,186

 
299,011

 
603,083

 
577,512

Selling, general and administrative expenses
147,253

 
147,795

 
299,690

 
298,235

Research and development expenses
30,352

 
34,404

 
59,731

 
68,402

Restructuring and contract termination charges, net
742

 
19,247

 
2,877

 
22,557

Operating income from continuing operations
69,637

 
40,216

 
121,399

 
76,910

Interest and other expense, net
8,964

 
12,865

 
20,253

 
24,905

Income from continuing operations before income taxes
60,673

 
27,351

 
101,146

 
52,005

Provision for (benefit from) income taxes
8,670

 
77

 
14,192

 
(8,044
)
Income from continuing operations
52,003

 
27,274

 
86,954

 
60,049

Loss from discontinued operations before income taxes
(2,084
)
 
(552
)
 
(3,114
)
 
(1,345
)
(Loss) gain on disposition of discontinued operations before income taxes
(302
)
 
613

 
(374
)
 
521

Income tax benefit from discontinued operations and dispositions
(873
)
 
(590
)
 
(1,248
)
 
(916
)
(Loss) gain on discontinued operations and dispositions
(1,513
)
 
651

 
(2,240
)
 
92

Net income
$
50,490

 
$
27,925

 
$
84,714

 
$
60,141

Basic earnings per share:
 
 
 
 
 
 
 
Income from continuing operations
$
0.46

 
$
0.24

 
$
0.77

 
$
0.53

(Loss) gain on discontinued operations and dispositions
(0.01
)
 
0.01

 
(0.02
)
 
0.00

Net income
$
0.45

 
$
0.25

 
$
0.75

 
$
0.53

Diluted earnings per share:
 
 
 
 
 
 
 
Income from continuing operations
$
0.46

 
$
0.24

 
$
0.76

 
$
0.53

(Loss) gain on discontinued operations and dispositions
(0.01
)
 
0.01

 
(0.02
)
 
0.00

Net income
$
0.44

 
$
0.25

 
$
0.74

 
$
0.53

Weighted average shares of common stock outstanding:
 
 
 
 
 
 
 
Basic
112,788

 
111,575

 
112,671

 
112,515

Diluted
113,971

 
112,718

 
113,874

 
113,717

Cash dividends per common share
$
0.07

 
$
0.07

 
$
0.14

 
$
0.14

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

Table of Contents

PERKINELMER, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
 
 
Three Months Ended
 
Six Months Ended
 
June 29,
2014
 
June 30,
2013
 
June 29,
2014
 
June 30,
2013
 
(In thousands)
Net income
$
50,490

 
$
27,925

 
$
84,714

 
$
60,141

Other comprehensive income:
 
 
 
 
 
 
 
Foreign currency translation adjustments
2,706

 
(1,201
)
 
3,340

 
(14,704
)
Reclassification adjustments for losses on derivatives included in net income, net of tax

 
299

 

 
598

Unrealized gains (losses) on securities, net of tax
2

 
(41
)
 
(30
)
 
(30
)
Other comprehensive income (loss)
2,708

 
(943
)
 
3,310

 
(14,136
)
Comprehensive income
$
53,198

 
$
26,982

 
$
88,024

 
$
46,005











The accompanying notes are an integral part of these condensed consolidated financial statements.



4

Table of Contents

PERKINELMER, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
 
 
June 29,
2014
 
December 29,
2013
 
(In thousands, except share and per share data)
Current assets:
 
 
 
Cash and cash equivalents
$
205,258

 
$
173,242

Accounts receivable, net
443,722

 
466,749

Inventories, net
277,991

 
260,858

Other current assets
151,715

 
140,342

Current assets of discontinued operations
1,963

 
3,647

Total current assets
1,080,649

 
1,044,838

Property, plant and equipment, net:
 
 
 
At cost
507,700

 
498,111

Accumulated depreciation
(328,024
)
 
(314,923
)
Property, plant and equipment, net
179,676

 
183,188

Marketable securities and investments
1,327

 
1,319

Intangible assets, net
417,308

 
460,430

Goodwill
2,141,819

 
2,143,120

Other assets, net
113,714

 
111,633

Long-term assets of discontinued operations
2,075

 
2,184

Total assets
$
3,936,568

 
$
3,946,712

Current liabilities:
 
 
 
Short-term debt
$
1,051

 
$
2,624

Accounts payable
155,415

 
166,881

Accrued restructuring and contract termination charges
14,676

 
26,374

Accrued expenses and other current liabilities
404,322

 
403,678

Current liabilities of discontinued operations
3,135

 
3,239

Total current liabilities
578,599

 
602,796

Long-term debt
894,282

 
932,104

Long-term liabilities
407,696

 
417,325

Total liabilities
1,880,577

 
1,952,225

Commitments and contingencies (see Note 19)

 

Stockholders’ equity:
 
 
 
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding

 

Common stock—$1 par value per share, authorized 300,000,000 shares; issued and outstanding 112,875,000 shares and 112,626,000 shares at June 29, 2014 and at December 29, 2013, respectively
112,875

 
112,626

Capital in excess of par value
108,962

 
119,906

Retained earnings
1,753,253

 
1,684,364

Accumulated other comprehensive income
80,901

 
77,591

Total stockholders’ equity
2,055,991

 
1,994,487

Total liabilities and stockholders’ equity
$
3,936,568

 
$
3,946,712

The accompanying notes are an integral part of these condensed consolidated financial statements.


5

Table of Contents

PERKINELMER, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited) 
 
Six Months Ended
 
June 29,
2014
 
June 30,
2013
 
(In thousands)
Operating activities:
 
 
 
Net income
$
84,714

 
$
60,141

Less: loss (gain) from discontinued operations and dispositions, net of income taxes
2,240

 
(92
)
Income from continuing operations
86,954

 
60,049

Adjustments to reconcile income from continuing operations to net cash provided by continuing operations:
 
 
 
Restructuring and contract termination charges, net
2,877

 
22,557

Depreciation and amortization
57,907

 
61,980

Stock-based compensation
9,319

 
7,642

Amortization of deferred debt issuance costs, interest rate hedges and accretion of discounts
662

 
1,680

Amortization of acquired inventory revaluation

 
203

Changes in operating assets and liabilities which provided (used) cash, excluding effects from companies purchased and divested:
Accounts receivable, net
23,434

 
15,489

Inventories, net
(15,737
)
 
(17,710
)
Accounts payable
(11,867
)
 
3,990

Accrued expenses and other
(30,979
)
 
(115,955
)
Net cash provided by operating activities of continuing operations
122,570

 
39,925

Net cash used in operating activities of discontinued operations
(464
)
 
(1,132
)
Net cash provided by operating activities
122,106

 
38,793

Investing activities:
 
 
 
Capital expenditures
(14,447
)
 
(22,852
)
Proceeds from surrender of life insurance policies
425

 
220

Activity related to acquisitions and investments, net of cash and cash equivalents acquired
(350
)
 
(49
)
Net cash used in investing activities of continuing operations
(14,372
)
 
(22,681
)
Net cash (used in) provided by investing activities of discontinued operations
(213
)
 
494

Net cash used in investing activities
(14,585
)
 
(22,187
)
Financing activities:
 
 
 
Payments on revolving credit facility
(232,000
)
 
(282,000
)
Proceeds from revolving credit facility
193,000

 
340,000

Payments of debt issuance costs
(1,845
)
 

Settlement of cash flow hedges

 
1,363

Net (payments on) proceeds from other credit facilities
(507
)
 
5,264

Proceeds from issuance of common stock under stock plans
19,454

 
7,289

Purchases of common stock
(38,976
)
 
(126,993
)
Dividends paid
(15,809
)
 
(15,892
)
Net cash used in financing activities
(76,683
)
 
(70,969
)
Effect of exchange rate changes on cash and cash equivalents
1,178

 
(4,611
)
Net increase (decrease) in cash and cash equivalents
32,016

 
(58,974
)
Cash and cash equivalents at beginning of period
173,242

 
171,444

Cash and cash equivalents at end of period
$
205,258

 
$
112,470

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

Table of Contents

PERKINELMER, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 1: Basis of Presentation
 
The condensed consolidated financial statements included herein have been prepared by PerkinElmer, Inc. (the “Company”), without audit, in accordance with accounting principles generally accepted in the United States of America (the “U.S.” or the "United States") and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information in the footnote disclosures of the financial statements has been condensed or omitted where it substantially duplicates information provided in the Company’s latest audited consolidated financial statements, in accordance with the rules and regulations of the SEC. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes included in its Annual Report on Form 10-K for the fiscal year ended December 29, 2013, filed with the SEC (the “2013 Form 10-K”). The balance sheet amounts at December 29, 2013 in this report were derived from the Company’s audited 2013 consolidated financial statements included in the 2013 Form 10-K. The condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods indicated. The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts and classifications of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three and six months ended June 29, 2014 and June 30, 2013, respectively, are not necessarily indicative of the results for the entire fiscal year or any future period. The Company has evaluated subsequent events from June 29, 2014 through the date of the issuance of these condensed consolidated financial statements and has determined that no material subsequent events have occurred that would affect the information presented in these condensed consolidated financial statements or would require additional disclosure.

Recently Adopted and Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s condensed consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations.

In April 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. Under this new guidance, only disposals of components of an entity that represent strategic shifts that have, or will have, a major effect on an entity's operations and financial results will be presented as discontinued operations. The standard also requires new disclosures related to individually significant disposals that do not meet the definition of a discontinued operation. The provisions of this guidance are effective for interim and annual periods beginning after December 15, 2014. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company’s condensed consolidated financial position, results of operations and cash flows.

In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers. Under this new guidance, an entity should use a five-step process to recognize revenue, which depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires new disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The provisions of this guidance are effective for interim and annual periods beginning after December 15, 2016. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company’s condensed consolidated financial position, results of operations and cash flows.

Note 2: Business Combinations

During fiscal year 2013, the Company completed the acquisition of four businesses for total consideration of $11.4 million, in cash. During the first six months of fiscal year 2014, the Company paid $0.4 million in additional deferred consideration for one of these acquisitions. As of the closing date of that acquisition, the Company potentially had to pay additional contingent consideration for the business of up to $2.2 million, which at closing had an estimated fair value of $1.1 million. The excess of the purchase prices over the fair values of each of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and have been allocated to goodwill, none of which is tax deductible. The Company reported the operations for these acquisitions within the results of the Company's operations from the acquisition dates. As of June 29, 2014, the purchase

7

Table of Contents

accounting allocations related to these acquisitions were preliminary, with the exception of those acquisitions completed during the first six months of fiscal year 2013.

The preliminary allocations of the purchase prices for these acquisitions were based upon initial valuations. The Company's estimates and assumptions underlying the initial valuations are subject to the collection of information necessary to complete the Company's valuations within the measurement periods, which are up to one year from the acquisition dates. The primary areas of the preliminary purchase price allocations that are not yet finalized relate to the fair value of certain tangible and intangible assets acquired and liabilities assumed, assets and liabilities related to income taxes and related valuation allowances, and residual goodwill. The Company expects to continue to obtain information to assist in determining the fair values of the net assets acquired at the acquisition dates during the measurement periods. During the measurement periods, the Company will adjust assets or liabilities if new information is obtained about facts and circumstances that existed as of the acquisition dates that, if known, would have resulted in the recognition of those assets and liabilities as of those dates. Adjustments to the preliminary allocations of the purchase prices during the measurement periods require the revision of comparative prior period financial information when reissued in subsequent financial statements. The effect of adjustments to the allocations of the purchase prices made during the measurement periods would be as if the adjustments had been completed on the acquisition dates. The effects of any such adjustments, if material, may cause changes in depreciation, amortization, or other income or expense recognized in prior periods. All changes that do not qualify as adjustments made during the measurement periods are included in current period earnings.
Allocations of the purchase price for acquisitions are based on estimates of the fair value of the net assets acquired and are subject to adjustment upon finalization of the purchase price allocations. The accounting for business combinations requires estimates and judgments as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair values for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash. Increases or decreases in the fair value of contingent consideration liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds or product development milestones during the earnout period. The Company may have to pay contingent consideration, related to all acquisitions with open contingency periods, of up to $28.6 million as of June 29, 2014. As of June 29, 2014, the Company has recorded contingent consideration obligations relating to its acquisitions of Dexela Limited, Haoyuan Biotech Co. and Tetra Teknolojik Sistemler Limited Sirketi, with an estimated fair value of $3.4 million. The earnout period for each of these acquisitions does not exceed three years from the respective acquisition date. If the actual results differ from the estimates and judgments used in these fair values, the amounts recorded in the condensed consolidated financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of definite-lived intangible assets or the recognition of additional consideration which would be expensed.
Total transaction costs related to acquisition activities for each of the three and six months ended June 29, 2014 were $0.1 million and $0.2 million, respectively. Total transaction costs related to acquisition activities were $0.1 million for each of the three and six months ended June 30, 2013. These transaction costs were expensed as incurred and recorded in selling, general and administrative expenses in the Company's condensed consolidated statements of operations.

Note 3: Discontinued Operations

As part of the Company’s continuing efforts to focus on higher growth opportunities, the Company has discontinued certain businesses. The Company has accounted for these businesses as discontinued operations and, accordingly, has presented the results of operations and related cash flows as discontinued operations for all periods presented. Any remaining assets and liabilities of these businesses have been presented separately, and are reflected within the assets and liabilities from discontinued operations in the accompanying condensed consolidated balance sheets as of June 29, 2014 and December 29, 2013.

8

Table of Contents

The Company recorded the following pre-tax gains and losses, which have been reported as a net gain or loss on disposition of discontinued operations:
 
Three Months Ended
 
Six Months Ended
 
June 29,
2014
 
June 30,
2013
 
June 29,
2014
 
June 30,
2013
 
(In thousands)
Loss on disposition of microarray-based diagnostic testing laboratory
$
(257
)
 
$

 
$
(257
)
 
$

Gain on disposition of Photoflash business

 
369

 

 
493

(Loss) gain on disposition of other discontinued operations
(45
)
 
244

 
(117
)
 
28

(Loss) gain on disposition of discontinued operations before income taxes
$
(302
)
 
$
613

 
$
(374
)
 
$
521

In May 2014, the Company’s management approved the shutdown of its microarray-based diagnostic testing laboratory in the United States, which has been reported within the Human Health segment. The Company determined that, with the lack of adequate reimbursement from health care payers, the microarray-based diagnostic testing laboratory in the United States would need significant investment in its operations to reduce costs in order to effectively compete in the market. The shutdown of the microarray-based diagnostic testing laboratory in the United States resulted in a $0.3 million pre-tax loss related to the disposal of fixed assets and inventory during the three months ended June 29, 2014.
In June 2010, the Company sold its Photoflash business, which was included in the Company's Environmental Health segment, for $13.5 million, including an adjustment for net working capital, plus potential additional contingent consideration. During the six months ended June 30, 2013, the Company recognized a pre-tax gain of $0.5 million for contingent consideration related to this sale. This gain was recognized as a gain on disposition of discontinued operations.
During the first six months of both fiscal years 2014 and 2013, the Company settled various commitments related to the divestiture of other discontinued operations. The Company recognized pre-tax gains and losses in the first six months of both fiscal years 2014 and 2013. These gains and losses were recognized as a (loss) gain on disposition of discontinued operations.
Summary pre-tax operating results of the discontinued operations for the periods prior to disposition, which included a $1.0 million pre-tax charge related to workforce reductions in the microarray-based diagnostic testing laboratory in the United States during the second quarter of fiscal year 2014, were as follows:
 
Three Months Ended
 
Six Months Ended
 
June 29,
2014
 
June 30,
2013
 
June 29,
2014
 
June 30,
2013
 
(In thousands)
Sales
$
426

 
$
2,624

 
$
1,720

 
$
5,059

Costs and expenses
2,510

 
3,176

 
4,834

 
6,404

Loss from discontinued operations before income taxes
$
(2,084
)
 
$
(552
)
 
$
(3,114
)
 
$
(1,345
)
The Company recorded a tax benefit of $0.9 million and a tax benefit of $1.2 million on discontinued operations and dispositions for the three and six months ended June 29, 2014, respectively. The Company recorded a tax benefit of $0.6 million and a tax benefit of $0.9 million on discontinued operations and dispositions for the three and six months ended June 30, 2013, respectively.

Note 4: Restructuring and Contract Termination Charges, Net

The Company has undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, alignment with the Company’s growth strategy, the integration of its business units and productivity initiatives. The current portion of restructuring and contract termination charges is recorded in accrued restructuring and contract termination charges and the long-term portion of restructuring and contract termination charges is recorded in long-term liabilities. The activities associated with these plans have been reported as restructuring and contract termination charges, net, and are included as a component of operating expenses from continuing operations.
A description of the restructuring plans and the activity recorded for the six months ended June 29, 2014 is listed below. Details of the plans initiated in previous years, particularly those listed under “Previous Restructuring and Integration Plans,” are discussed more fully in Note 4 to the audited consolidated financial statements in the 2013 Form 10-K.

9

Table of Contents

The restructuring plans for the first and second quarters of fiscal year 2014 and the first quarter of fiscal year 2013 were principally intended to focus resources on higher growth end markets. The restructuring plans for the fourth and third quarters of fiscal year 2013 were principally intended to shift certain of the Company's research and development resources into a newly opened Center for Innovation. The restructuring plan for the second quarter of fiscal year 2013 was principally intended to shift certain of the Company's operations into a newly established shared service center as well as realign operations, research and development resources and production resources as a result of previous acquisitions.

A description of the restructuring plans and the activity recorded are as follows:

Q2 2014 Restructuring Plan
During the second quarter of fiscal year 2014, the Company’s management approved a plan to focus resources on higher growth end markets (the “Q2 2014 Plan”). As a result of the Q2 2014 Plan, the Company recognized a $0.5 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and recognized a $0.3 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities. As part of the Q2 2014 Plan, the Company reduced headcount by 22 employees. All employees were notified of termination under the Q2 2014 Plan by June 29, 2014.

The following table summarizes the Q2 2014 Plan activity for the six months ended June 29, 2014:
 
Severance
 
(In thousands)
Provision
$
735

Amounts paid and foreign currency translation
(228
)
Balance at June 29, 2014
$
507

The Company anticipates that the remaining severance payments of $0.5 million for workforce reductions will be substantially completed by the end of the second quarter of fiscal year 2015.

Q1 2014 Restructuring Plan
During the first quarter of fiscal year 2014, the Company’s management approved a plan principally intended to focus resources on higher growth end markets (the “Q1 2014 Plan”). As a result of the Q1 2014 Plan, the Company recognized a $0.4 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and recognized a $0.2 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities. As part of the Q1 2014 Plan, the Company reduced headcount by 17 employees. All employees were notified of termination under the Q1 2014 Plan by March 30, 2014.

The following table summarizes the Q1 2014 Plan activity for the six months ended June 29, 2014:
 
Severance
 
(In thousands)
Provision
$
567

Amounts paid and foreign currency translation
(345
)
Balance at June 29, 2014
$
222

The Company anticipates that the remaining severance payments of $0.2 million for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2014.

Q4 2013 Restructuring Plan
During the fourth quarter of fiscal year 2013, the Company’s management approved a plan principally intended to shift certain of the Company's research and development resources into a newly opened Center for Innovation (the “Q4 2013 Plan”). As a result of the Q4 2013 Plan, the Company recognized an $8.2 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space and recognized a $3.0 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities. As part of the Q4 2013 Plan, the Company reduced headcount by 73 employees. All employees were notified of termination under the Q4 2013 Plan by December 29, 2013.


10

Table of Contents

The following table summarizes the Q4 2013 Plan activity for the six months ended June 29, 2014:
 
Severance
 
Closure of
Excess Facility
Space
 
Total
 
(In thousands)
Balance at December 29, 2013
$
1,987

 
$
6,854

 
$
8,841

Amounts paid and foreign currency translation
(1,456
)
 
(900
)
 
(2,356
)
Balance at June 29, 2014
$
531

 
$
5,954

 
$
6,485


The Company anticipates that the remaining severance payments of $0.5 million for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2014. The Company also anticipates that the remaining payments of $6.0 million, net of estimated sublease income, for the closure of the excess facility space will be paid through fiscal year 2019, in accordance with the terms of the applicable leases.

Q3 2013 Restructuring Plan
During the third quarter of fiscal year 2013, the Company’s management approved a plan principally intended to shift certain of the Company's research and development resources into a newly opened Center for Innovation (the “Q3 2013 Plan”). As a result of the Q3 2013 Plan, the Company recognized a $0.5 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space. As part of the Q3 2013 Plan, the Company reduced headcount by 29 employees. All employees were notified of termination under the Q3 2013 Plan by September 29, 2013.

The following table summarizes the Q3 2013 Plan activity for the six months ended June 29, 2014:
 
Severance
 
(In thousands)
Balance at December 29, 2013
$
137

Amounts paid and foreign currency translation
(133
)
Balance at June 29, 2014
$
4

 
The severance payments for workforce reductions were substantially completed by the end of the second quarter of fiscal year 2014.

Q2 2013 Restructuring Plan
During the second quarter of fiscal year 2013, the Company’s management approved a plan principally intended to shift certain of the Company's operations into a newly established shared service center as well as realign operations, research and development resources, and production resources as a result of previous acquisitions (the “Q2 2013 Plan”). As a result of the Q2 2013 Plan, the Company initially recognized a $9.9 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space, and recognized a $8.8 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space. Subsequent to the initial charge, during fiscal year 2013, the Company recorded an additional $0.6 million pre-tax restructuring charge in the Human Health segment for services that were provided for one-time benefits in which the employee was required to render service beyond the legal notification period. During the six months ended June 29, 2014, the Company recorded additional pre-tax restructuring charges of $0.1 million in each of the Human Health and Environmental Health segments due to higher than expected costs associated with the closure of the excess facility space. As part of the Q2 2013 Plan, the Company reduced headcount by 264 employees. All employees were notified of termination under the Q2 2013 Plan by June 30, 2013.
 

11

Table of Contents

The following table summarizes the Q2 2013 Plan activity for the six months ended June 29, 2014:
 
Severance
 
Closure of
Excess Facility
Space
 
Total
 
(In thousands)
Balance at December 29, 2013
$
12,750

 
$

 
$
12,750

Change in estimates

 
184

 
184

Amounts paid and foreign currency translation
(7,798
)
 
(137
)
 
(7,935
)
Balance at June 29, 2014
$
4,952

 
$
47

 
$
4,999

 
The Company anticipates that the remaining severance payments of $5.0 million for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2014, as local law requires some severance to be paid in monthly installments through the fourth quarter of fiscal year 2014. The Company also anticipates that the remaining payments of $0.05 million for the closure of the excess facility space will be paid through the third quarter of 2014, in accordance with the terms of the applicable lease.

Q1 2013 Restructuring Plan
During the first quarter of fiscal year 2013, the Company’s management approved a plan to focus resources on higher growth end markets (the “Q1 2013 Plan”). As a result of the Q1 2013 Plan, the Company recognized a $2.3 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and recognized a $0.2 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities. During the six months ended June 29, 2014, the Company recorded a pre-tax restructuring reversal of $0.2 million in the Human Health segment due to lower than expected costs associated with the remaining severance payments. As part of the Q1 2013 Plan, the Company reduced headcount by 62 employees. All employees were notified of termination under the Q1 2013 Plan by March 31, 2013.
 
The following table summarizes the Q1 2013 Plan activity for the six months ended June 29, 2014:
 
Severance
 
(In thousands)
Balance at December 29, 2013
$
208

Change in estimates
(208
)
Balance at June 29, 2014
$

 
No remaining severance payments exist under the Q1 2013 Plan.

Previous Restructuring and Integration Plans
The principal actions of the restructuring and integration plans from fiscal year 2001 through fiscal year 2012 were workforce reductions and the closure of excess facility space related to the integration of the Company’s businesses in order to realign operations, reduce costs, achieve operational efficiencies and shift resources into geographic regions and end markets that are more consistent with the Company’s growth strategy. During the six months ended June 29, 2014, the Company paid $3.6 million related to these plans and recorded an additional charge of $0.1 million related to higher than expected costs associated with workforce reductions within the Human Health Segment. As of June 29, 2014, the Company had $9.7 million of remaining liabilities associated with these restructuring and integration plans, primarily for residual lease obligations related to closed facilities and remaining severance payments for workforce reductions in both the Human Health and Environmental Health segments. The Company expects to make payments for these leases, the terms of which vary in length, through fiscal year 2022. The Company anticipates the remaining severance payments for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2014, as local law requires some severance to be paid in monthly installments through the fourth quarter of fiscal year 2014.

Contract Termination Charges
The Company has terminated various contractual commitments in connection with certain disposal activities and has recorded charges, to the extent applicable, for the costs of terminating these contracts before the end of their terms and the costs that will continue to be incurred for the remaining terms without economic benefit to the Company. The Company recorded an additional pre-tax charge of $1.5 million, primarily as a result of terminating various contractual commitments in the

12

Table of Contents

Environmental Health segment, and the Company made payments for these obligations of $1.2 million in the first six months of fiscal year 2014. The remaining balance of these accruals as of June 29, 2014 was $0.6 million.

Note 5: Interest and Other Expense, Net

Interest and other expense, net, consisted of the following:
 
Three Months Ended
 
Six Months Ended
 
June 29,
2014
 
June 30,
2013
 
June 29,
2014
 
June 30,
2013
 
(In thousands)
Interest income
$
(151
)
 
$
(64
)
 
$
(245
)
 
$
(169
)
Interest expense
9,079

 
11,913

 
18,298

 
23,606

Other expense, net
36

 
1,016

 
2,200

 
1,468

Total interest and other expense, net
$
8,964

 
$
12,865

 
$
20,253

 
$
24,905


Note 6: Inventories, Net

Inventories as of June 29, 2014 and December 29, 2013 consisted of the following:
 
June 29,
2014
 
December 29,
2013
 
(In thousands)
Raw materials
$
97,293

 
$
92,713

Work in progress
17,356

 
15,505

Finished goods
163,342

 
152,640

Total inventories, net
$
277,991

 
$
260,858


Note 7: Income Taxes

The Company regularly reviews its tax positions in each significant taxing jurisdiction in the process of evaluating its unrecognized tax benefits. The Company makes adjustments to its unrecognized tax benefits when: (i) facts and circumstances regarding a tax position change, causing a change in management’s judgment regarding that tax position; (ii) a tax position is effectively settled with a tax authority at a differing amount; and/or (iii) the statute of limitations expires regarding a tax position.
At June 29, 2014, the Company had gross tax effected unrecognized tax benefits of $33.9 million, of which $28.6 million, if recognized, would affect the continuing operations effective tax rate. The remaining amount, if recognized, would affect discontinued operations.
The Company believes that it is reasonably possible that approximately $2.4 million of its uncertain tax positions at June 29, 2014, including accrued interest and penalties, and net of tax benefits, may be resolved over the next twelve months as a result of lapses in applicable statutes of limitations and potential settlements. Various tax years after 2006 remain open to examination by certain jurisdictions in which the Company has significant business operations, such as China, Finland, Germany, Italy, Netherlands, Singapore, the United Kingdom and the United States. The tax years under examination vary by jurisdiction.
During the first six months of fiscal years 2014 and 2013, the Company recorded net discrete income tax benefits of $4.0 million and $15.4 million, respectively, primarily for reversals of uncertain tax position reserves and resolution of other tax matters. The $15.4 million discrete income tax benefits for the six months ended June 30, 2013 included $9.4 million of reversals as a result of lapses in statutes of limitation during the first quarter of fiscal year 2013.

Note 8: Debt

Senior Unsecured Revolving Credit Facility. On January 8, 2014, the Company refinanced its debt held under a previous senior unsecured revolving credit facility and entered into a new senior unsecured revolving credit facility. The new senior unsecured revolving credit facility provides for $700.0 million of revolving loans and has an initial maturity of January 8, 2019. As of June 29, 2014, undrawn letters of credit in the aggregate amount of $12.2 million were treated as issued and outstanding under the new senior unsecured revolving credit facility. As of June 29, 2014, the Company had $329.8 million available for

13

Table of Contents

additional borrowing under the new facility. The Company uses the senior unsecured revolving credit facility for general corporate purposes, which may include working capital, refinancing existing indebtedness, capital expenditures, share repurchases, acquisitions and strategic alliances. The interest rates under the senior unsecured revolving credit facility are based on the Eurocurrency rate or the base rate at the time of borrowing, plus a margin. The base rate is the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by JP Morgan Chase Bank, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) one-month Libor plus 1.00%. At June 29, 2014, borrowings under the senior unsecured revolving credit facility were accruing interest based on the Eurocurrency rate. The Eurocurrency margin as of June 29, 2014 was 108 basis points. The weighted average Eurocurrency interest rate as of June 29, 2014 was 0.18%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 1.26%. At June 29, 2014, the Company had $358.0 million of borrowings in U.S. Dollars outstanding under the senior unsecured revolving credit facility. The credit agreement for the facility contains affirmative, negative and financial covenants and events of default similar to those contained in the Company's credit agreement for its previous facility. The financial covenants in the Company's senior unsecured revolving credit facility include a debt-to-capital ratio, and two contingent covenants, a maximum consolidated leverage ratio and a minimum consolidated interest coverage ratio, applicable if the Company's credit rating is downgraded below investment grade. During the six months ended June 29, 2014, the Company capitalized $1.8 million of debt issuance costs for the refinancing of debt held under its previous senior unsecured revolving credit facility. These debt issuance costs are being amortized into interest and other expense, net, on a straight-line basis, over the term of the new senior unsecured revolving credit facility.

The Company's previous senior unsecured revolving credit facility provided for $700.0 million of revolving loans and had an initial maturity of December 16, 2016. At December 29, 2013, the Company had $397.0 million of borrowings in U.S. Dollars outstanding under the previous senior unsecured revolving credit facility. The credit agreement for the previous facility contained affirmative, negative and financial covenants and events of default similar to those contained in the Company's new credit facility.
5% Senior Unsecured Notes due in 2021. On October 25, 2011, the Company issued $500.0 million aggregate principal amount of senior unsecured notes due in 2021 (the “2021 Notes”) in a registered public offering and received $496.9 million of net proceeds from the issuance. The 2021 Notes were issued at 99.372% of the principal amount, which resulted in a discount of $3.1 million. As of June 29, 2014, the 2021 Notes had an aggregate carrying value of $497.5 million, net of $2.5 million of unamortized original issue discount. As of December 29, 2013, the 2021 Notes had an aggregate carrying value of $497.4 million, net of $2.6 million of unamortized original issue discount. The 2021 Notes mature in November 2021 and bear interest at an annual rate of 5%. Interest on the 2021 Notes is payable semi-annually on May 15th and November 15th each year. Prior to August 15, 2021 (three months prior to their maturity date), the Company may redeem the 2021 Notes in whole or in part, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the 2021 Notes to be redeemed, plus accrued and unpaid interest, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the 2021 Notes being redeemed, discounted on a semi-annual basis, at the Treasury Rate plus 45 basis points, plus accrued and unpaid interest. At any time on or after August 15, 2021 (three months prior to their maturity date), the Company may redeem the 2021 Notes, at its option, at a redemption price equal to 100% of the principal amount of the 2021 Notes to be redeemed plus accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the 2021 Notes ) and a contemporaneous downgrade of the 2021 Notes below investment grade, each holder of 2021 Notes will have the right to require the Company to repurchase such holder's 2021 Notes for 101% of their principal amount, plus accrued and unpaid interest.
Financing Lease Obligations. In September 2012, the Company entered into agreements with the lessors of certain buildings that the Company is currently occupying and leasing to expand those buildings. The Company provided a portion of the funds needed for the construction of the additions to the buildings, which resulted in the Company being considered the owner of the buildings during the construction period. At the end of the construction period, the Company was not reimbursed by the lessors for all of the construction costs. The Company is therefore deemed to have continuing involvement and the leases qualify as financing leases under sale-leaseback accounting guidance, representing debt obligations for the Company and non-cash investing and financing activities. As a result, the Company capitalized $29.3 million in property and equipment, net, representing the fair value of the buildings with a corresponding increase to debt. The Company has also capitalized $11.5 million in additional construction costs necessary to complete the renovations to the buildings, which were funded by the lessors, with a corresponding increase to debt. At June 29, 2014, the Company had $39.8 million recorded for these financing lease obligations, of which $1.1 million was recorded as short-term debt and $38.7 million was recorded as long-term debt. At December 29, 2013, the Company had $40.3 million recorded for these financing lease obligations, of which $2.6 million was recorded as short-term debt and $37.7 million was recorded as long-term debt. The buildings are being depreciated on a straight-line basis over the terms of the leases to their estimated residual values, which will equal the remaining financing obligation at the end of the lease term. At the end of the lease term, the remaining balances in property, plant and equipment, net and debt will be reversed against each other.

14

Table of Contents


Note 9: Earnings Per Share

Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations:
 
Three Months Ended
 
Six Months Ended
 
June 29,
2014
 
June 30,
2013
 
June 29,
2014
 
June 30,
2013
 
(In thousands)
Number of common shares—basic
112,788

 
111,575

 
112,671

 
112,515

Effect of dilutive securities:
 
 
 
 
 
 
 
Stock options
970

 
913

 
1,010

 
981

Restricted stock awards
213

 
230

 
193

 
221

Number of common shares—diluted
113,971

 
112,718

 
113,874

 
113,717

Number of potentially dilutive securities excluded from calculation due to antidilutive impact
499

 
535

 
479

 
507

Antidilutive securities include outstanding stock options with exercise prices and average unrecognized compensation cost in excess of the average fair market value of common stock for the related period. Antidilutive options were excluded from the calculation of diluted net income per share and could become dilutive in the future.

Note 10: Industry Segment Information

The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income. Intersegment revenue and transfers are not significant. The Company’s management reviews the results of the Company’s operations by the Human Health and Environmental Health operating segments. The accounting policies of the operating segments are the same as those described in Note 1 to the audited consolidated financial statements in the 2013 Form 10-K. The principal products and services of the Company's two operating segments are:
Human Health.    Develops diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. The Human Health segment serves both the diagnostics and research markets.
Environmental Health.    Provides products, services and solutions to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets.
The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments.

15

Table of Contents

Revenue and operating income (loss) by operating segment, excluding discontinued operations, are shown in the table below: 
 
Three Months Ended
 
Six Months Ended
 
June 29,
2014
 
June 30,
2013
 
June 29,
2014
 
June 30,
2013
 
(In thousands)
Human Health
 
 
 
 
 
 
 
Product revenue
$
245,108

 
$
235,923

 
$
484,137

 
$
454,996

Service revenue
62,397

 
61,396

 
121,557

 
121,217

Total revenue
307,505

 
297,319

 
605,694

 
576,213

Operating income from continuing operations
52,614

 
30,628

 
96,704

 
56,441

Environmental Health
 
 
 
 
 
 
 
Product revenue
136,501

 
138,101

 
262,956

 
265,647

Service revenue
112,164

 
105,253

 
218,130

 
201,756

Total revenue
248,665

 
243,354

 
481,086

 
467,403

Operating income from continuing operations
30,872

 
19,298

 
52,371

 
40,026

Corporate
 
 
 
 
 
 
 
Operating loss from continuing operations(1)
(13,849
)
 
(9,710
)
 
(27,676
)
 
(19,557
)
Continuing Operations
 
 
 
 
 
 
 
Product revenue
381,609

 
374,024

 
747,093

 
720,643

Service revenue
174,561

 
166,649

 
339,687

 
322,973

Total revenue
556,170

 
540,673

 
1,086,780

 
1,043,616

Operating income from continuing operations
69,637

 
40,216

 
121,399

 
76,910

Interest and other expense, net (see Note 5)
8,964

 
12,865

 
20,253

 
24,905

Income from continuing operations before income taxes
$
60,673

 
$
27,351

 
$
101,146

 
$
52,005

____________________________
(1) 
Activity related to the mark-to-market adjustment on postretirement benefit plans has been included in the Corporate operating loss from continuing operations, and in the aggregate constituted a pre-tax gain of $0.1 million for both the six months ended June 29, 2014 and June 30, 2013. There were no expenses related to the mark-to-market adjustment on postretirement benefit plans for either the three months ended June 29, 2014 or June 30, 2013.

Note 11: Stockholders’ Equity
Comprehensive Income:
The components of accumulated other comprehensive income consisted of the following:
 
June 29,
2014
 
December 29,
2013
 
(In thousands)
Foreign currency translation adjustments
$
79,623

 
$
76,283

Unrecognized prior service costs, net of income taxes
1,429

 
1,429

Unrealized net losses on securities, net of income taxes
(151
)
 
(121
)
Accumulated other comprehensive income
$
80,901

 
$
77,591

In December 2013, the Company redeemed all of its 6% senior unsecured notes due in 2015 and wrote-off the remaining unamortized derivative losses for previously settled cash flow hedges. During the six months ended June 30, 2013, pre-tax losses of $1.0 million were reclassified from accumulated other comprehensive income into interest and other expense, net related to previously settled cash flow hedges. The Company recognized a tax benefit of $0.4 million related to these amounts reclassified out of accumulated other comprehensive income for the six months ended June 30, 2013.

Stock Repurchase Program:
On October 24, 2012, the Board of Directors ("the Board") authorized the Company to repurchase up to 6.0 million shares of common stock under a stock repurchase program (the "Repurchase Program"). The Repurchase Program will expire on October 24, 2014 unless terminated earlier by the Board, and may be suspended or discontinued at any time. During the six

16

Table of Contents

months ended June 29, 2014, the Company repurchased 0.8 million shares of common stock in the open market at an aggregate cost of $34.8 million, including commissions, under the Repurchase Program. As of June 29, 2014, 1.7 million shares of the Company’s common stock remained available for repurchase from the 6.0 million shares authorized by the Board under the Repurchase Program.
The Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans and to satisfy obligations related to the exercise of stock options made pursuant to the Company's equity incentive plans. During the six months ended June 29, 2014, the Company repurchased 97,174 shares of common stock for this purpose at an aggregate cost of $4.2 million. The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value.

Dividends:
The Board declared a regular quarterly cash dividend of $0.07 per share for each of the first two quarters of fiscal year 2014 and in each quarter of fiscal year 2013. At June 29, 2014, the Company has accrued $7.9 million for dividends declared on April 22, 2014 for the second quarter of fiscal year 2014, payable in August 2014. On July 24, 2014, the Company announced that the Board had declared a quarterly dividend of $0.07 per share for the third quarter of fiscal year 2014 that will be payable in November 2014. In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Note 12: Stock Plans

In addition to the Company's Employee Stock Purchase Plan, the Company utilizes one stock-based compensation plan, the 2009 Incentive Plan (the “2009 Plan”). Under the 2009 Plan, 10.0 million shares of the Company's common stock are authorized for stock option grants, restricted stock awards, performance units and stock grants as part of the Company’s compensation programs. In addition to shares of the Company’s common stock originally authorized for issuance under the 2009 Plan, the 2009 Plan includes shares of the Company’s common stock previously granted under the Amended and Restated 2001 Incentive Plan and the 2005 Incentive Plan that were canceled or forfeited without the shares being issued.
The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance units and stock grants, net of estimated forfeitures, included in the Company’s condensed consolidated statements of operations for the three and six months ended June 29, 2014 and June 30, 2013:
 
Three Months Ended
 
Six Months Ended
 
June 29,
2014
 
June 30,
2013
 
June 29,
2014
 
June 30,
2013
 
(In thousands)
Cost of product and service revenue
$
337

 
$
307

 
$
671

 
$
620

Research and development expenses
220

 
211

 
360

 
426

Selling, general and administrative expenses
4,246

 
2,708

 
8,288

 
6,596

Total stock-based compensation expense
$
4,803

 
$
3,226

 
$
9,319

 
$
7,642

The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $1.8 million and $3.5 million for the three and six months ended June 29, 2014, respectively. The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $1.0 million and $2.4 million for the three and six months ended June 30, 2013, respectively. Stock-based compensation costs capitalized as part of inventory were $0.4 million and $0.3 million as of June 29, 2014 and June 30, 2013, respectively. The excess tax benefit recognized from stock compensation, classified as a financing cash activity, was zero for both the six months ended June 29, 2014 and June 30, 2013.

17

Table of Contents

Stock Options: The fair value of each option grant is estimated using the Black-Scholes option pricing model. The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows:
 
Three and Six Months Ended
 
June 29,
2014
 
June 30,
2013
Risk-free interest rate
1.5
%
 
0.9
%
Expected dividend yield
0.7
%
 
0.8
%
Expected lives
5 years

 
5 years

Expected stock volatility
30.9
%
 
38.5
%
The following table summarizes stock option activity for the six months ended June 29, 2014:
 
Number
of
Shares
 
Weighted-
Average
Price
 
Weighted-Average
Remaining
Contractual Term
 
Total
Intrinsic
Value
 
(In thousands)
 
 
 
(In years)
 
(In millions)
Outstanding at December 29, 2013
3,494

 
$
23.34

 
 
 
 
Granted
511

 
43.06

 
 
 
 
Exercised
(814
)
 
23.89

 
 
 
 
Canceled
(4
)
 
20.97

 
 
 
 
Forfeited
(44
)
 
33.70

 
 
 
 
Outstanding at June 29, 2014
3,143

 
$
26.26

 
3.9
 
$
58.5

Exercisable at June 29, 2014
2,108

 
$
21.40

 
2.9
 
$
49.5

Vested and expected to vest in the future
3,099

 
$
26.15

 
3.9
 
$
58.0

The weighted-average per-share grant-date fair value of options granted during the three and six months ended June 29, 2014 was $11.80 and $11.84, respectively The weighted-average per-share grant-date fair value of options granted during the three and six months ended June 30, 2013 was $9.82 and $10.82, respectively. The total intrinsic value of options exercised during the three and six months ended June 29, 2014 was $11.1 million and $17.6 million, respectively. The total intrinsic value of options exercised during the three and six months ended June 30, 2013 was $1.0 million and $4.1 million, respectively. Cash received from option exercises for the six months ended June 29, 2014 and June 30, 2013 was $19.5 million and $7.3 million, respectively.
The total compensation expense recognized related to the Company’s outstanding options was $1.4 million and $2.9 million for the three and six months ended June 29, 2014, respectively, and $0.8 million and $2.1 million for the three and six months ended June 30, 2013, respectively.
There was $8.7 million of total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock options granted as of June 29, 2014. This cost is expected to be recognized over a weighted-average period of 2.1 years and will be adjusted for any future changes in estimated forfeitures.
Restricted Stock Awards: The following table summarizes restricted stock award activity for the six months ended June 29, 2014:
 
Number of
Shares
 
Weighted-
Average
Grant-
Date Fair
Value
 
(In thousands)
 
 
Nonvested at December 29, 2013
649

 
$
29.24

Granted
235

 
42.61

Vested
(254
)
 
27.65

Forfeited
(38
)
 
33.12

Nonvested at June 29, 2014
592

 
$
34.98


18

Table of Contents

The weighted-average per-share grant-date fair value of restricted stock awards granted during the three and six months ended June 29, 2014 was $43.19 and $42.61, respectively. The weighted-average per-share grant-date fair value of restricted stock awards granted during the three and six months ended June 30, 2013 was $32.34 and $33.70, respectively. The fair value of restricted stock awards vested during the three and six months ended June 29, 2014 was $0.2 million and $7.0 million, respectively. The fair value of restricted stock awards vested during the three and six months ended June 30, 2013 was $0.3 million and $7.2 million, respectively. The total compensation expense recognized related to the Company’s outstanding restricted stock awards was $1.9 million and $3.9 million for the three and six months ended June 29, 2014, respectively, and $1.7 million and $3.9 million for the three and six months ended June 30, 2013, respectively.
As of June 29, 2014, there was $14.0 million of total unrecognized compensation cost, net of forfeitures, related to nonvested restricted stock awards. That cost is expected to be recognized over a weighted-average period of 1.6 years.
Performance Units: The Company granted 79,463 and 98,056 performance units during the six months ended June 29, 2014 and June 30, 2013, respectively, as part of the Company’s executive incentive program. The weighted-average per-share grant-date fair value of performance units granted during the six months ended June 29, 2014 and June 30, 2013 was $42.84 and $34.06, respectively. The total compensation expense recognized related to these performance units was $0.7 million and $1.7 million for the three and six months ended June 29, 2014, respectively, and zero and $0.9 million for the three and six months ended June 30, 2013, respectively. As of June 29, 2014, there were 271,679 performance units outstanding and subject to forfeiture, with a corresponding liability of $4.4 million recorded in accrued expenses and other current liabilities.
Stock Awards: The Company generally grants stock awards only to non-employee members of the Board. The Company granted 2,373 shares and 3,263 shares to each non-employee member of the Board during the six months ended June 29, 2014 and June 30, 2013, respectively. The weighted-average per-share grant-date fair value of the stock awards granted during the six months ended June 29, 2014 and June 30, 2013 was $42.14 and $30.65, respectively. The total compensation expense recognized related to these stock awards was $0.7 million for each of the six months ended June 29, 2014 and June 30, 2013.
Employee Stock Purchase Plan: During the six months ended June 29, 2014, the Company issued 31,854 shares of common stock under the Company's Employee Stock Purchase Plan at a weighted-average price of $39.17 per share. During the six months ended June 30, 2013, the Company issued 89,521 shares of common stock under the Company's Employee Stock Purchase Plan at a weighted-average price of $30.51 per share. At June 29, 2014, an aggregate of 1.1 million shares of the Company’s common stock remained available for sale to employees out of the 5.0 million shares authorized by shareholders for issuance under this plan.

Note 13: Goodwill and Intangible Assets, Net
 
The Company tests goodwill and non-amortizing intangible assets at least annually for possible impairment. Accordingly, the Company completes the annual testing of impairment for goodwill and non-amortizing intangible assets on the later of January 1 or the first day of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill or non-amortizing intangible assets.
The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of a two-step process. The first step is the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. The second step measures the amount of an impairment loss, and is only performed if the carrying value exceeds the fair value of the reporting unit. The Company performed its annual impairment testing for its reporting units as of January 1, 2014, its annual impairment date for fiscal year 2014. The Company concluded based on the first step of the process that there was no goodwill impairment, and the fair value exceeded the carrying value by more than 90.0% for each reporting unit, with the exception of the life sciences and technology reporting unit where the fair value exceeded the carrying value by approximately 11.0%. The carrying value of the goodwill for the life sciences and technology reporting unit was $796.3 million, at the annual impairment date for fiscal year 2014.
The Company has consistently employed the income approach to estimate the current fair value when testing for impairment of goodwill. A number of significant assumptions and estimates are involved in the application of the income approach to forecast operating cash flows, including markets and market share, sales volumes and prices, costs to produce, tax rates, capital spending, discount rate and working capital changes. Cash flow forecasts are based on approved business unit operating plans for the early years’ cash flows and historical relationships in later years. The income approach is sensitive to changes in long-term terminal growth rates and the discount rates. The long-term terminal growth rates are consistent with the Company’s historical long-term terminal growth rates, as the current economic trends are not expected to affect the long-term terminal growth rates of the Company. The long-term terminal growth rates for the Company’s reporting units ranged from 3.0% to 6.0% for the fiscal year 2014 impairment analysis. The range for the discount rates for the reporting units was approximately 10.0% to 11.5%. Keeping all other variables constant, a 10.0% change in any one of the input assumptions for

19

Table of Contents

the various reporting units would still allow the Company to conclude, based on the first step of the process, that there was no impairment of goodwill.
During the second quarter of 2014, the Company realigned its organization which resulted in a change in the composition of the Company's reporting units within the Human Health segment. The Company's informatics business was moved from the life sciences and technology reporting unit to its own reporting unit. As a result of the new alignment, the Company reallocated goodwill based on the relative fair value, determined using the income approach, of each of these businesses. The change resulted in $192.6 million of goodwill being reallocated from the life sciences and technology reporting unit to the informatics reporting unit as of June 29, 2014. As of June 29, 2014, the Company concluded based on the first step of the process that there was no goodwill impairment for either the life sciences and technology reporting unit or the informatics reporting unit, and the fair value exceeded the carrying value by more than 20.0% for each of these reporting units.
The Company has consistently employed the relief from royalty model to estimate the current fair value when testing for impairment of non-amortizing intangible assets. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized. In addition, the Company currently evaluates the remaining useful life of its non-amortizing intangible assets at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful lives of non-amortizing intangible assets are no longer indefinite, the assets will be tested for impairment. These intangible assets will then be amortized prospectively over their estimated remaining useful lives and accounted for in the same manner as other intangible assets that are subject to amortization. The Company performed its annual impairment testing as of January 1, 2014, and concluded that there was no impairment of non-amortizing intangible assets. An assessment of the recoverability of amortizing intangible assets takes place when events have occurred that may give rise to an impairment. No such events occurred during the first six months of fiscal year 2014.
The changes in the carrying amount of goodwill for the period ended June 29, 2014 from December 29, 2013 were as follows:
 
Human
Health
 
Environmental
Health
 
Consolidated
 
(In thousands)
Balance at December 29, 2013
$
1,648,332

 
$
494,788

 
$
2,143,120

Foreign currency translation
(1,006
)
 
(295
)
 
(1,301
)
Balance at June 29, 2014
$
1,647,326

 
$
494,493

 
$
2,141,819


20

Table of Contents

Identifiable intangible asset balances at June 29, 2014 and December 29, 2013 by category were as follows:
 
June 29,
2014
 
December 29,
2013
 
(In thousands)
Patents
$
39,591

 
$
39,591

Less: Accumulated amortization
(25,522
)
 
(24,207
)
Net patents
14,069

 
15,384

Trade names and trademarks
35,021

 
35,809

Less: Accumulated amortization
(17,119
)
 
(16,208
)
Net trade names and trademarks
17,902

 
19,601

Licenses
79,173

 
79,180

Less: Accumulated amortization
(57,415
)
 
(52,930
)
Net licenses
21,758

 
26,250

Core technology
302,530

 
302,070

Less: Accumulated amortization
(187,315
)
 
(169,326
)
Net core technology
115,215

 
132,744

Customer relationships
321,701

 
321,395

Less: Accumulated amortization
(150,734
)
 
(132,833
)
Net customer relationships
170,967

 
188,562

IPR&D
9,492

 
9,483

Less: Accumulated amortization
(2,679
)
 
(2,178
)
Net IPR&D
6,813

 
7,305

Net amortizable intangible assets
346,724

 
389,846

Non-amortizing intangible assets:
 
 
 
Trade names and trademarks
70,584

 
70,584

Total
$
417,308

 
$
460,430

Total amortization expense related to definite-lived intangible assets was $20.6 million and $41.3 million for the three and six months ended June 29, 2014, respectively, and $22.0 million and $44.2 million for the three and six months June 30, 2013, respectively. Estimated amortization expense related to definite-lived intangible assets for each of the next five years is $41.9 million for the remainder of fiscal year 2014, $69.2 million in fiscal year 2015, $60.2 million in fiscal year 2016, $50.7 million in fiscal year 2017, and $39.1 million in fiscal year 2018.

Note 14: Warranty Reserves

The Company provides warranty protection for certain products usually for a period of one year beyond the date of sale. The majority of costs associated with warranty obligations include the replacement of parts and the time for service personnel to respond to repair and replacement requests. A warranty reserve is recorded based upon historical results, supplemented by management’s expectations of future costs. Warranty reserves are included in “Accrued expenses and other current liabilities” on the condensed consolidated balance sheets.

21

Table of Contents

A summary of warranty reserve activity for the three and six months ended June 29, 2014 and June 30, 2013 is as follows:
 
Three Months Ended
 
Six Months Ended
 
June 29,
2014
 
June 30,
2013
 
June 29,
2014
 
June 30,
2013
 
(In thousands)
Balance beginning of period
$
10,357

 
$
10,827

 
$
10,534

 
$
11,003

Provision charged to income
4,332

 
4,173

 
8,409

 
8,513

Payments
(4,388
)
 
(3,843
)
 
(8,355
)
 
(8,667
)
Adjustments to previously provided warranties, net
471

 
(688
)
 
174

 
(323
)
Foreign currency translation and acquisitions
14

 
(18
)
 
24

 
(75
)
Balance end of period
$
10,786

 
$
10,451

 
$
10,786

 
$
10,451


Note 15: Employee Postretirement Benefit Plans

The following table summarizes the components of net periodic benefit cost (credit) for the Company’s various defined benefit employee pension and postretirement plans for the three and six months ended June 29, 2014 and June 30, 2013:
 
Defined Benefit
Pension Benefits
 
Postretirement
Medical Benefits
 
Three Months Ended
 
June 29,
2014
 
June 30,
2013
 
June 29,
2014
 
June 30,
2013
 
(In thousands)
Service cost
$
1,034

 
$
916

 
$
24

 
$
28

Interest cost
5,931

 
5,298

 
39

 
36

Expected return on plan assets
(6,280
)
 
(6,253
)
 
(241
)
 
(241
)
Amortization of prior service costs
(71
)
 
(67
)
 

 

Net periodic benefit cost (credit)
$
614

 
$
(106
)
 
$
(178
)
 
$
(177
)
 
Defined Benefit
Pension Benefits
 
Postretirement
Medical Benefits
 
Six Months Ended
 
June 29,
2014
 
June 30,
2013
 
June 29,
2014
 
June 30,
2013
 
(In thousands)
Service cost
$
2,064

 
$
1,841

 
$
48

 
$
56

Interest cost
11,847

 
10,613

 
77

 
72

Expected return on plan assets
(12,543
)
 
(12,517
)
 
(482
)
 
(482
)
Amortization of prior service
(142
)
 
(134
)
 

 

Net periodic benefit cost (credit)
$
1,226

 
$
(197
)
 
$
(357
)
 
$
(354
)
During the first six months of fiscal year 2014, the Company contributed $1.9 million, in the aggregate, to plans outside of the United States.
If required, a mark-to-market adjustment will be recorded in the fourth quarter of fiscal year 2014 in accordance with the Company's accounting method for defined benefit pension plans and other postretirement benefits as described in Note 1 of the Company's audited consolidated financial statements and notes included in its 2013 Form 10-K.

Note 16: Derivatives and Hedging Activities

The Company uses derivative instruments as part of its risk management strategy only, and includes derivatives utilized as economic hedges that are not designated as hedging instruments. By nature, all financial instruments involve market and credit risks. The Company enters into derivative instruments with major investment grade financial institutions and has policies to monitor the credit risk of those counterparties. The Company does not enter into derivative contracts for trading or other

22

Table of Contents

speculative purposes, nor does the Company use leveraged financial instruments. Approximately 60% of the Company’s business is conducted outside of the United States, generally in foreign currencies. The fluctuations in foreign currency can increase the costs of financing, investing and operating the business. The intent of these economic hedges is to offset gains and losses that occur on the underlying exposures from these currencies, with gains and losses resulting from the forward currency contracts that hedge these exposures.
In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months, have no cash requirements until maturity, and are recorded at fair value on the Company’s condensed consolidated balance sheets. Unrealized gains and losses on the Company’s foreign currency contracts are recognized immediately in earnings for hedges designated as fair value and, for hedges designated as cash flow, the related unrealized gains or losses are deferred as a component of other comprehensive income in the accompanying condensed consolidated balance sheets. Deferred gains and losses are recognized in income in the period in which the underlying anticipated transaction occurs and impacts earnings.
Principal hedged currencies include the British Pound, Euro, Japanese Yen and Singapore Dollar. The Company held forward foreign exchange contracts, designated as fair value hedges, with U.S. equivalent notional amounts totaling $109.7 million, $138.4 million and $69.0 million at June 29, 2014, December 29, 2013 and June 30, 2013, respectively, and the fair value of these foreign currency derivative contracts was insignificant. The gains and losses realized on foreign currency derivative contracts are not material. The duration of these contracts was generally 30 days or less during both fiscal years 2014 and 2013.
In December 2012, the Company entered into forward foreign exchange contracts with settlement dates in fiscal year 2013 and combined Euro denominated notional amounts of €50.0 million, designated as cash flow hedges. During the first two quarters of fiscal year 2013, the Company settled these Euro denominated forward foreign exchange contracts. The derivative gains were amortized into interest and other expense, net, when the hedged exposures affected interest and other expense, net. Such amounts were not material for the three and six months ended June 30, 2013.

Note 17: Fair Value Measurements

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities and accounts receivable. The Company believes it had no significant concentrations of credit risk as of June 29, 2014.
The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during the six months ended June 29, 2014. The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition-related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value.
Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.

23

Table of Contents

The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of June 29, 2014 and December 29, 2013 classified in one of the three classifications described above:
 
Fair Value Measurements at June 29, 2014 Using:
 
Total Carrying Value at June 29, 2014
 
Quoted Prices in
Active Markets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
(In thousands)
Marketable securities
$
1,327

 
$
1,327

 
$

 
$

Foreign exchange derivative assets
36

 

 
36

 

Foreign exchange derivative liabilities
(203
)
 

 
(203
)
 

Contingent consideration
(3,430
)
 

 

 
(3,430
)
 
 
Fair Value Measurements at December 29, 2013 Using:
 
Total Carrying Value at December 29, 2013
 
Quoted Prices in
Active Markets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable 
Inputs
(Level 3)
 
(In thousands)
Marketable securities
$
1,319

 
$
1,319

 
$

 
$

Foreign exchange derivative assets
293

 

 
293

 

Foreign exchange derivative liabilities
(396
)
 

 
(396
)
 

Contingent consideration
(4,926
)
 

 

 
(4,926
)
Level 1 and Level 2 Valuation Techniques:    The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity and fixed-income securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities. 
Marketable securities:    Include equity and fixed-income securities measured at fair value using the quoted market prices in active markets at the reporting date.
Foreign exchange derivative assets and liabilities:    Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date. The Company’s foreign exchange derivative contracts are subject to master netting arrangements that allow the Company and its counterparties to net settle amounts owed to each other. Derivative assets and liabilities that can be net settled under these arrangements have been presented in the Company's consolidated balance sheet on a net basis and are recorded in other assets. As of both June 29, 2014 and December 29, 2013, none of the master netting arrangements involved collateral.
Level 3 Valuation Techniques:    The Company’s Level 3 liabilities are comprised of contingent consideration related to acquisitions. For liabilities that utilize Level 3 inputs, the Company uses significant unobservable inputs. Below is a summary of valuation techniques for Level 3 liabilities.
Contingent consideration:    The Company has classified its net liabilities for contingent consideration relating to its acquisitions within Level 3 of the fair value hierarchy because the fair value is determined using significant unobservable inputs, which included probability weighted cash flows. A description of the significant acquisitions is included within Note 2 to the Company's audited consolidated financial statements filed with the 2013 Form 10-K. Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period. Increases or decreases in the fair value of contingent consideration liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds or product development milestones during the earnout period. The Company may have to pay contingent consideration, related to all acquisitions with open contingency periods, of up to $28.6 million as of June 29, 2014. As of June 29, 2014, the Company has recorded contingent consideration obligations relating to its acquisitions of Dexela Limited, Haoyuan Biotech Co. and Tetra Teknolojik Sistemler Limited Sirketi, with an estimated fair value of $3.4 million at June 29, 2014. The earnout period for each of these acquisitions does not exceed three years from the respective acquisition date, and the remaining weighted average earnout period at June 29, 2014 was one year.

24

Table of Contents

A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows:
 
Three Months Ended
 
Six Months Ended
 
June 29,
2014
 
June 30,
2013
 
June 29,
2014
 
June 30,
2013
 
(In thousands)
Balance beginning of period
$
(4,981
)
 
$
(2,727
)
 
$
(4,926
)
 
$
(3,017
)
Additions

 
(1,100
)
 

 
(1,100
)
Amounts paid and foreign currency translation
(72
)
 

 
(72
)
 
64

Change in fair value (included within selling, general and administrative expenses)
1,623

 
112

 
1,568

 
338

Balance end of period
$
(3,430
)
 
$
(3,715
)
 
$
(3,430
)
 
$
(3,715
)
The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1.
The Company’s new senior unsecured revolving credit facility, which provides for $700.0 million of revolving loans, had amounts outstanding, excluding letters of credit, of $358.0 million as of June 29, 2014. The Company’s previous senior unsecured revolving credit facility had amounts outstanding, excluding letters of credit, of $397.0 million as of December 29, 2013. The interest rate on the Company’s senior unsecured revolving credit facility is reset at least monthly to correspond to variable rates that reflect currently available terms and conditions for similar debt. The Company had no change in credit standing during the first six months of fiscal year 2014. Consequently, the carrying value of the current year and prior year credit facilities approximate fair value and would be classified as Level 2. 
The Company's 2021 Notes, with a face value of $500.0 million, had an aggregate carrying value of $497.5 million, net of $2.5 million of unamortized original issue discount, and a fair value of $533.2 million as of June 29, 2014. The 2021 Notes had an aggregate carrying value of $497.4 million, net of $2.6 million of unamortized original issue discount, and a fair value of $513.0 million as of December 29, 2013. The fair value of the 2021 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. The Company's financing lease obligations had an aggregate carrying value of $39.8 million and $40.3 million as of June 29, 2014 and December 29, 2013, respectively, which approximated their fair value as there has been minimal change in the Company's incremental borrowing rate. As of June 29, 2014, the 2021 Notes and financing lease obligations were classified as Level 2.
As of June 29, 2014, there has not been any significant impact to the fair value of the Company’s derivative liabilities due to credit risk. Similarly, there has not been any significant adverse impact to the Company’s derivative assets based on the evaluation of its counterparties’ credit risks.

Note 18: Leases

On August 22, 2013, the Company sold one of its facilities located in Boston, Massachusetts for net proceeds of $47.6 million. Simultaneously with the closing of the sale of the property, the Company entered into a lease agreement to lease back the property for its continued use. The lease has an initial term of 15 years and the Company has the right to extend the term of the lease for two additional periods of ten years each. The lease is accounted for as an operating lease and at the transaction date the Company had deferred $26.5 million of gains which are being amortized in operating expenses over the initial lease term of 15 years. During the six months ended June 29, 2014, the Company amortized $0.9 million of deferred gains related to the lease. At June 29, 2014, $25.0 million of these deferred gains remained to be amortized, which were recorded in long-term liabilities. At December 29, 2013, $25.9 million of deferred gains remained to be amortized, which were recorded in long-term liabilities.

Note 19: Contingencies

The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (“PRP”) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company’s responsibility is established and when the cost can be reasonably estimated. The Company has accrued $12.0 million and $13.5 million as of June 29, 2014 and December 29, 2013, respectively, which represents management’s estimate of the cost of the remediation of known environmental matters, and does not include any potential liability for related personal injury or property damage claims. This amount is not discounted and does not reflect the recovery of any material amounts through insurance or

25

Table of Contents

indemnification arrangements. These cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that the majority of such accrued amounts could be paid out over a period of up to ten years. As assessment and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had, or are expected to have, a material adverse effect on the Company’s condensed consolidated financial statements. While it is possible that a loss exceeding the amounts recorded in the condensed consolidated financial statements may be incurred, the potential exposure is not expected to be materially different from those amounts recorded.
Enzo Biochem, Inc. and Enzo Life Sciences, Inc. (collectively, “Enzo”) filed a complaint dated October 23, 2002 in the United States District Court for the Southern District of New York, Civil Action No. 02-8448, seeking injunctive and monetary relief against Amersham plc, Amersham BioSciences, PerkinElmer, Inc., PerkinElmer Life Sciences, Inc., Sigma-Aldrich Corporation, Sigma Chemical Company, Inc., Molecular Probes, Inc., and Orchid BioSciences, Inc. The complaint alleges that the Company breached its distributorship and settlement agreements with Enzo, infringed Enzo's patents, engaged in unfair competition and fraud, and committed torts against Enzo by, among other things, engaging in commercial development and exploitation of Enzo's patented products and technology, separately and together with the other defendants. The Company filed an answer and a counterclaim alleging that Enzo's patents are invalid. In 2007, after the court issued a decision in 2006 regarding the construction of the claims in Enzo's patents that effectively limited the coverage of certain of those claims and, the Company believes, excluded certain of the Company's products from the coverage of Enzo's patents, summary judgment motions were filed by the defendants. The case was assigned to a new district court judge in January 2009 and in March 2009, the new judge denied the pending summary judgment motions without prejudice and ordered a stay of the case until the federal appellate court decided Enzo's appeal of the judgment of the United States District Court for the District of Connecticut in Enzo Biochem vs. Applera Corp. and Tropix, Inc. (the “Connecticut Case”), which involved a number of the same patents and which could materially affect the scope of Enzo's case against the Company. In March 2010, the United States Court of Appeals for the Federal Circuit affirmed-in-part and reversed-in-part the judgment in the Connecticut Case. The district court permitted the Company and the other defendants to jointly file a motion for summary judgment on certain patent and other issues common to all of the defendants. On September 12, 2012, the court granted in part and denied in part the Company's motion for summary judgment of non-infringement. On December 21, 2012, the Company filed a second motion for summary judgment on claims that were not addressed in the first motion, which the court also granted in part and denied in part. The Company expected this case to go to trial in March 2014 and incurred $0.1 million and $3.4 million of expenses in preparation for the trial during the three and six months ended June 29, 2014, respectively. Following a delay in the trial date, the Company subsequently entered into a settlement agreement with Enzo dated June 20, 2014 and in the third quarter of fiscal year 2014 paid $7.0 million into a designated escrow account to resolve this matter, of which $3.7 million had been previously accrued.
The Company is also subject to various other claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of its business activities. Although the Company has established accruals for potential losses that it believes are probable and reasonably estimable, in the opinion of the Company’s management, based on its review of the information available at this time, the total cost of resolving these other contingencies at June 29, 2014 should not have a material adverse effect on the Company’s condensed consolidated financial statements. However, each of these matters is subject to uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company.

26

Table of Contents

Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
This quarterly report on Form 10-Q, including the following management’s discussion and analysis, contains forward-looking information that you should read in conjunction with the condensed consolidated financial statements and notes to the condensed consolidated financial statements that we have included elsewhere in this report. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “plans,” “anticipates,” “intends,” “expects,” “will” and similar expressions are intended to identify forward-looking statements. Our actual results may differ materially from the plans, intentions or expectations we disclose in the forward-looking statements we make. We have included important factors below under the heading “Risk Factors” in Part II, Item 1A. that we believe could cause actual results to differ materially from the forward-looking statements we make. We are not obligated to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Overview
We are a leading provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. Through our advanced technologies, solutions, and services, we address critical issues that help to improve the health and safety of people and their environment. The principal products and services of our two operating segments are:
Human Health.    Develops diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. Our Human Health segment serves both the diagnostics and research markets.
Environmental Health.    Provides products, services and solutions to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. Our Environmental Health segment serves the environmental, industrial and laboratory services markets.
Overview of the Second Quarter of Fiscal Year 2014
Our fiscal year ends on the Sunday nearest December 31. We report fiscal years under a 52/53 week format, and as a result certain fiscal years will contain 53 weeks. Both our 2014 and 2013 fiscal years include 52 weeks.
Our overall revenue in the second quarter of fiscal year 2014 was $556.2 million and increased $15.5 million, or 3%, as compared to the second quarter of fiscal year 2013, reflecting an increase of $10.2 million, or 3%, in our Human Health segment revenue and an increase of $5.3 million, or 2%, in our Environmental Health segment revenue. The increase in our Human Health segment revenue during the second quarter of fiscal year 2014 was primarily due to growth generated from our newborn screening business within the diagnostics market. The increase in our Environmental Health segment revenue during the second quarter of fiscal year 2014 was due to an increase in our service revenue, which included our OneSource multivendor service offerings within our laboratory service market.
In our Human Health segment during the second quarter of fiscal year 2014 as compared to the second quarter of fiscal year 2013, we experienced growth in the diagnostics market from continued expansion of our prenatal, newborn and infectious disease screening solutions in key regions outside the United States, particularly in emerging markets such as China. Birth rates continue to increase, as evidenced by prenatal trends we saw during the second quarter of fiscal year 2014, and demand for greater access to newborn screening in rural areas is also increasing. Our medical imaging business increased during the second quarter of fiscal year 2014 as compared to the second quarter of fiscal year 2013 due to growth in industrial non-destructive testing and adoption of digital x-ray technology in radiography. In the research market we experienced slight declines due to weakness in the global academic end market specifically in Europe and China. China also experienced government funding delays due to regulatory reorganization and anti-corruption activities coupled with slower disbursement by provincial agencies that also negatively impacted the growth in the research market. As the rising cost of healthcare continues to be one of the critical issues facing our customers, we anticipate that the benefits of providing earlier detection of disease, which can result in savings of long-term health care costs as well as create better outcomes for patients, are increasingly valued and we expect to see continued growth in these markets.
In our Environmental Health segment, our laboratory services business offers services designed to enable our customers to increase efficiencies and production time, while reducing maintenance costs, all of which continue to be critical for our customers. During the second quarter of fiscal year 2014, we continued to grow our laboratory services business, which included the addition of new customers to our OneSource multivendor service offering, while revenue across our products in the environmental and industrial markets declined slightly, partly due to government funding delays in China. We anticipate that the continued development of contaminant regulations and corresponding testing protocols will result in increased demand for efficient, analytically sensitive and information rich testing solutions.

27

Table of Contents

Our consolidated gross margins decreased 11 basis points in the second quarter of fiscal year 2014, as compared to the second quarter of fiscal year 2013, due to unfavorable changes in product mix, with an increase in sales of lower gross margin product offerings, which were partially offset by increased sales volume and cost containment and productivity initiatives. Our consolidated operating margins increased 508 basis points in the second quarter of fiscal year 2014, as compared to the second quarter of fiscal year 2013, primarily due to cost containment and productivity initiatives, which were partially offset by lower gross margins.
We believe we are well positioned to continue to take advantage of the spending trends in our end markets and to promote our efficiencies in markets where current conditions may increase demand for certain services. Overall, we believe that our strategic focus on Human Health and Environmental Health coupled with our breadth of end markets, deep portfolio of technologies and applications, leading market positions, global scale and financial strength will provide us with a foundation for growth.

Critical Accounting Policies and Estimates
The preparation of condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, warranty costs, bad debts, inventories, accounting for business combinations and dispositions, long-lived assets, income taxes, restructuring, pensions and other postretirement benefits, contingencies and litigation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
Critical accounting policies are those policies that affect our more significant judgments and estimates used in the preparation of our condensed consolidated financial statements. We believe our critical accounting policies include our policies regarding revenue recognition, warranty costs, allowances for doubtful accounts, inventory valuation, business combinations, value of long-lived assets, including goodwill and other intangibles, employee compensation and benefits, restructuring activities, gains or losses on dispositions and income taxes.
For a more detailed discussion of our critical accounting policies and estimates, please refer to the Notes to our Audited Consolidated Financial Statements and Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our Annual Report on Form 10-K for the fiscal year ended December 29, 2013 (our “2013 Form 10-K”), as filed with the Securities and Exchange Commission (the "SEC"). There have been no significant changes in our critical accounting policies and estimates during the six months ended June 29, 2014.

Consolidated Results of Continuing Operations
Revenue
Revenue for the three months ended June 29, 2014 was $556.2 million, as compared to $540.7 million for the three months ended June 30, 2013, an increase of $15.5 million, or 3%, which includes an approximate 1% increase in revenue attributable to favorable changes in foreign exchange rates and an approximate 1% increase from acquisitions. The analysis in the remainder of this paragraph compares segment revenue for the three months ended June 29, 2014 as compared to the three months ended June 30, 2013 and includes the effect of foreign exchange rate fluctuations and acquisitions. Our Human Health segment revenue increased $10.2 million, or 3%, due to an increase in diagnostics market revenue of $12.3 million, partially offset by a decrease in research market revenue of $2.1 million. Our Environmental Health segment revenue increased $5.3 million, or 2%, due to an increase in laboratory services market revenue of $6.9 million, partially offset by decreases in environmental and industrial markets revenue of $1.6 million. As a result of adjustments to deferred revenue related to certain acquisitions required by business combination rules, we did not recognize $0.4 million of revenue for the three months ended June 29, 2014 and $3.8 million for the three months ended June 30, 2013 that otherwise would have been recorded by the acquired businesses during each of the respective periods.
Revenue for the six months ended June 29, 2014 was $1,086.8 million, as compared to $1,043.6 million for the six months ended June 30, 2013, an increase of $43.2 million, or 4%, which includes an approximate 0.3% increase in revenue attributable to favorable changes in foreign exchange rates and an approximate 0.4% increase from acquisitions. The analysis in the remainder of this paragraph compares segment revenue for the six months ended June 29, 2014 as compared to the six months ended June 30, 2013 and includes the effect of foreign exchange rate fluctuations and acquisitions. Our Human Health segment revenue increased $29.5 million, or 5%, due to an increase in diagnostics market revenue of $23.9 million and an increase in research market revenue of $5.6 million. Our Environmental Health segment revenue increased $13.7 million, or 3%, due to an increase in laboratory services market revenue of $16.4 million, partially offset by decreases in environmental and industrial markets revenue of $2.7 million. As a result of adjustments to deferred revenue related to certain acquisitions

28

Table of Contents

required by business combination rules, we did not recognize $1.9 million of revenue for the six months ended June 29, 2014 and $5.7 million for the six months ended June 30, 2013 that otherwise would have been recorded by the acquired businesses during each of the respective periods.
Cost of Revenue
Cost of revenue for the three months ended June 29, 2014 was $308.2 million, as compared to $299.0 million for the three months ended June 30, 2013, an increase of $9.2 million, or 3%. As a percentage of revenue, cost of revenue increased to 55.4% for the three months ended June 29, 2014, from 55.3% for the three months ended June 30, 2013, resulting in a decrease in gross margin of 11 basis points to 44.6% for the three months ended June 29, 2014, from 44.7% for the three months ended June 30, 2013. Amortization of intangible assets decreased and was $12.3 million for the three months ended June 29, 2014, as compared to $12.5 million for the three months ended June 30, 2013. Stock-based compensation expense was $0.3 million for each of the three months ended June 29, 2014 and June 30, 2013. Acquisition related costs were an expense of $0.02 million for the three months ended June 29, 2014. The amortization of purchase accounting adjustments to record the inventory from certain acquisitions was an expense of $0.1 million for the three months ended June 30, 2013. In addition to the above items, the overall decrease in gross margin was primarily the result of unfavorable changes in product mix, with an increase in sales of lower gross margin product offerings, which were partially offset by increased sales volume and cost containment and productivity initiatives.
Cost of revenue for the six months ended June 29, 2014 was $603.1 million, as compared to $577.5 million for the six months ended June 30, 2013, an increase of $25.6 million, or 4%. As a percentage of revenue, cost of revenue increased to 55.5% for the six months ended June 29, 2014, from 55.3% for the six months ended June 30, 2013, resulting in a decrease in gross margin of 16 basis points to 44.5% for the six months ended June 29, 2014, from 44.7% for the six months ended June 30, 2013. Amortization of intangible assets decreased and was $25.0 million for the six months ended June 29, 2014, as compared to $25.1 million for the six months ended June 30, 2013. Stock-based compensation expense was $0.7 million for the six months ended June 29, 2014, as compared to $0.6 million for the six months ended June 30, 2013. Acquisition related costs were an expense of $0.03 million for the six months ended June 29, 2014. The amortization of purchase accounting adjustments to record the inventory from certain acquisitions was an expense of $0.2 million for the six months ended June 30, 2013. In addition to the above items, the overall decrease in gross margin was primarily the result of pricing pressure and unfavorable changes in product mix with an increase in sales of lower gross margin product offerings, partially offset by increased sales volume and cost containment and productivity initiatives.
Selling, General and Administrative Expenses
Selling, general and administrative expenses for the three months ended June 29, 2014 were $147.3 million, as compared to $147.8 million for the three months ended June 30, 2013, a decrease of $0.5 million, or 0.4%. As a percentage of revenue, selling, general and administrative expenses decreased and were 26.5% for the three months ended June 29, 2014, as compared to 27.3% for the three months ended June 30, 2013. Amortization of intangible assets decreased and was $8.1 million for the three months ended June 29, 2014, as compared to $9.5 million for the three months ended June 30, 2013. Stock-based compensation expense increased and was $4.2 million for the three months ended June 29, 2014, as compared to $2.7 million for the three months ended June 30, 2013. Significant settlement and litigation expenses related to a particular case were $3.4 million for the three months ended June 29, 2014. Acquisition related costs for contingent consideration and other acquisition costs decreased expenses by $1.5 million for the three months ended June 29, 2014, as compared to an incremental expense of $0.1 million for the three months ended June 30, 2013. In addition to the above items, the decrease in selling, general and administrative expenses was primarily the result of cost containment and productivity initiatives.
Selling, general and administrative expenses for the six months ended June 29, 2014 were $299.7 million, as compared to $298.2 million for the six months ended June 30, 2013, an increase of $1.5 million, or 0.5%. As a percentage of revenue, selling, general and administrative expenses decreased and were 27.6% for the six months ended June 29, 2014, as compared to 28.6% for the six months ended June 30, 2013. Amortization of intangible assets decreased and was $16.0 million for the six months ended June 29, 2014, as compared to $19.0 million for the six months ended June 30, 2013. Stock-based compensation expense increased and was $8.3 million for the six months ended June 29, 2014, as compared to $6.6 million for the six months ended June 30, 2013. Significant settlement and litigation expenses related to a particular case were $6.6 million for the six months ended June 29, 2014. Acquisition related costs for contingent consideration and other acquisition costs decreased expenses by $1.4 million for the six months ended June 29, 2014, as compared to an incremental expense of $0.1 million for the six months ended June 30, 2013. In addition to the above items, the increase in selling, general and administrative expenses was primarily the result of costs related to growth and productivity investments, particularly in emerging territories, partially offset by cost containment and productivity initiatives.

29

Table of Contents

Research and Development Expenses
Research and development expenses for the three months ended June 29, 2014 were $30.4 million, as compared to $34.4 million for the three months ended June 30, 2013, a decrease of $4.1 million, or 12%. As a percentage of revenue, research and development expenses decreased and were 5.5% for the three months ended June 29, 2014, as compared to 6.4% for the three months ended June 30, 2013. Amortization of intangible assets was $0.1 million for each of the three months ended June 29, 2014 and June 30, 2013. Stock-based compensation expense was $0.2 million for each of the three months ended June 29, 2014 and June 30, 2013. In addition to the above items, the decrease in research and development expenses was primarily the result of the consolidation of research and development activities into our newly opened Center for Innovation. During the first six months of both fiscal year 2014 and fiscal year 2013, we directed research and development efforts toward the diagnostics and research markets within our Human Health segment, and the environmental, industrial and laboratory service markets within our Environmental Health segment, in order to help accelerate our growth initiatives.
Research and development expenses for the six months ended June 29, 2014 were $59.7 million, as compared to $68.4 million for the six months ended June 30, 2013, a decrease of $8.7 million, or 13%. As a percentage of revenue, research and development expenses decreased and were 5.5% for the six months ended June 29, 2014, as compared to 6.6% for the six months ended June 30, 2013. Amortization of intangible assets increased and was $0.3 million for the six months ended June 29, 2014, as compared to $0.1 million for the six months ended June 30, 2013. Stock-based compensation expense was $0.4 million for each of the six months ended June 29, 2014 and the six months ended June 30, 2013. In addition to the above items, the decrease in research and development expenses was primarily the result of the consolidation of research and development activities into our newly opened Center for Innovation.

Restructuring and Contract Termination Charges, Net
We have undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, alignment with our growth strategy, the integration of our business units and productivity initiatives. The current portion of restructuring and contract termination charges is recorded in accrued restructuring and contract termination charges and the long-term portion of restructuring and contract termination charges is recorded in long-term liabilities. The activities associated with these plans have been reported as restructuring and contract termination charges, net, and are included as a component of operating expenses from continuing operations.
A description of the restructuring plans and the activity recorded for the six months ended June 29, 2014 is listed below. Details of the plans initiated in previous years, particularly those listed under “Previous Restructuring and Integration Plans,” are discussed more fully in Note 4 to the audited consolidated financial statements in the 2013 Form 10-K.
The restructuring plans for the first and second quarters of fiscal year 2014 and the first quarter of fiscal year 2013 were principally intended to focus resources on higher growth end markets. The restructuring plans for the fourth and third quarters of fiscal year 2013 were principally intended to shift certain of our research and development resources into a newly opened Center for Innovation. The restructuring plan for the second quarter of fiscal year 2013 was principally intended to shift certain of our operations into a newly established shared service center as well as realign operations, research and development resources and production resources as a result of previous acquisitions. We expect the impact of future cost savings on operating results and cash flows from the restructuring activities executed in fiscal year 2013 will exceed $9.0 million annually beginning in fiscal year 2015. The future cost savings will be primarily a decrease to research and development expenses.

A description of the restructuring plans and the activity recorded are as follows:

Q2 2014 Restructuring Plan
During the second quarter of fiscal year 2014, our management approved a plan to focus resources on higher growth end markets (the “Q2 2014 Plan”). As a result of the Q2 2014 Plan, we recognized a $0.5 million pre-tax restructuring charge in our Human Health segment related to a workforce reduction from reorganization activities and recognized a $0.3 million pre-tax restructuring charge in our Environmental Health segment related to a workforce reduction from reorganization activities. As part of the Q2 2014 Plan, we reduced headcount by 22 employees. All employees were notified of termination under the Q2 2014 Plan by June 29, 2014.


30

Table of Contents

The following table summarizes the Q2 2014 Plan activity for the six months ended June 29, 2014:
 
Severance
 
(In thousands)
Provision
$
735

Amounts paid and foreign currency translation
(228
)
Balance at June 29, 2014
$
507

We anticipate that the remaining severance payments of $0.5 million for workforce reductions will be substantially completed by the end of the second quarter of fiscal year 2015.

Q1 2014 Restructuring Plan
During the first quarter of fiscal year 2014, our management approved a plan principally intended to focus resources on higher growth end markets (the “Q1 2014 Plan”). As a result of the Q1 2014 Plan, we recognized a $0.4 million pre-tax restructuring charge in our Human Health segment related to a workforce reduction from reorganization activities and recognized a $0.2 million pre-tax restructuring charge in our Environmental Health segment related to a workforce reduction from reorganization activities. As part of the Q1 2014 Plan, we reduced headcount by 17 employees. All employees were notified of termination under the Q1 2014 Plan by March 30, 2014.
 
The following table summarizes the Q1 2014 Plan activity for the six months ended June 29, 2014:
 
Severance
 
(In thousands)
Provision
$
567

Amounts paid and foreign currency translation
(345
)
Balance at June 29, 2014
$
222

We anticipate that the remaining severance payments of $0.2 million for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2014.

Q4 2013 Restructuring Plan
During the fourth quarter of fiscal year 2013, our management approved a plan principally intended to shift certain of our research and development resources into a newly opened Center for Innovation (the “Q4 2013 Plan”). As a result of the Q4 2013 Plan, we recognized an $8.2 million pre-tax restructuring charge in our Human Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space and recognized a $3.0 million pre-tax restructuring charge in our Environmental Health segment related to a workforce reduction from reorganization activities. As part of the Q4 2013 Plan, we reduced headcount by 73 employees. All employees were notified of termination under the Q4 2013 Plan by December 29, 2013.

The following table summarizes the Q4 2013 Plan activity for the six months ended June 29, 2014:
 
Severance
 
Closure of
Excess Facility
Space
 
Total
 
(In thousands)
Balance at December 29, 2013
$
1,987

 
$
6,854

 
$
8,841

Amounts paid and foreign currency translation
(1,456
)
 
(900
)
 
(2,356
)
Balance at June 29, 2014
$
531

 
$
5,954

 
$
6,485

 
We anticipate that the remaining severance payments of $0.5 million for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2014. We also anticipate that the remaining payments of $6.0 million, net of estimated sublease income, for the closure of the excess facility space will be paid through fiscal year 2019, in accordance with the terms of the applicable leases.


31

Table of Contents

Q3 2013 Restructuring Plan
During the third quarter of fiscal year 2013, our management approved a plan principally intended to shift certain of our research and development resources into a newly opened Center for Innovation (the “Q3 2013 Plan”). As a result of the Q3 2013 Plan, we recognized a $0.5 million pre-tax restructuring charge in our Human Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space. As part of the Q3 2013 Plan, we reduced headcount by 29 employees. All employees were notified of termination under the Q3 2013 Plan by September 29, 2013.
 
The following table summarizes the Q3 2013 Plan activity for the six months ended June 29, 2014:
 
Severance
 
(In thousands)
Balance at December 29, 2013
$
137

Amounts paid and foreign currency translation
(133
)
Balance at June 29, 2014
$
4

 
The severance payments for workforce reductions were substantially completed by the end of the second quarter of fiscal year 2014.

Q2 2013 Restructuring Plan
During the second quarter of fiscal year 2013, our management approved a plan principally intended to shift certain of our operations into a newly established shared service center as well as realign operations, research and development resources, and production resources as a result of previous acquisitions (the “Q2 2013 Plan”). As a result of the Q2 2013 Plan, we initially recognized a $9.9 million pre-tax restructuring charge in our Human Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space, and recognized a $8.8 million pre-tax restructuring charge in our Environmental Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space. Subsequent to the initial charge, during fiscal year 2013, we recorded an additional $0.6 million pre-tax restructuring charge in our Human Health segment for services that were provided for one-time benefits in which the employee was required to render service beyond the legal notification period. During the six months ended June 29, 2014, we recorded additional pre-tax restructuring charges of $0.1 million in each of our Human Health and Environmental Health segments due to higher than expected costs associated with the closure of the excess facility space. As part of the Q2 2013 Plan, we reduced headcount by 264 employees. All employees were notified of termination under the Q2 2013 Plan by June 30, 2013.
 
The following table summarizes the Q2 2013 Plan activity for the six months ended June 29, 2014:
 
Severance
 
Closure of
Excess Facility
Space
 
Total
 
(In thousands)
Balance at December 29, 2013
$
12,750

 
$

 
$
12,750

Change in estimates

 
184

 
184

Amounts paid and foreign currency translation
(7,798
)
 
(137
)
 
(7,935
)
Balance at June 29, 2014
$
4,952

 
$
47

 
$
4,999

 
We anticipate that the remaining severance payments of $5.0 million for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2014, as local law requires some severance to be paid in monthly installments through the fourth quarter of fiscal year 2014. We also anticipate that the remaining payments of $0.05 million for the closure of the excess facility space will be paid through the third quarter of 2014, in accordance with the terms of the applicable lease.

Q1 2013 Restructuring Plan
During the first quarter of fiscal year 2013, our management approved a plan to focus resources on higher growth end markets (the “Q1 2013 Plan”). As a result of the Q1 2013 Plan, we recognized a $2.3 million pre-tax restructuring charge in our Human Health segment related to a workforce reduction from reorganization activities and recognized a $0.2 million pre-tax restructuring charge in our Environmental Health segment related to a workforce reduction from reorganization activities. During the six months ended June 29, 2014, we recorded a pre-tax restructuring reversal of $0.2 million in our Human Health segment due to lower than expected costs associated with the remaining severance payments. As part of the Q1 2013 Plan, we reduced headcount by 62 employees. All employees were notified of termination under the Q1 2013 Plan by March 31, 2013.

32

Table of Contents

 
The following table summarizes the Q1 2013 Plan activity for the six months ended June 29, 2014:
 
Severance
 
(In thousands)
Balance at December 29, 2013
$
208

Change in estimates
(208
)
Balance at June 29, 2014
$

 
No remaining severance payments exist under the Q1 2013 Plan.

Previous Restructuring and Integration Plans
The principal actions of the restructuring and integration plans from fiscal year 2001 through fiscal year 2012 were workforce reductions and the closure of excess facility space related to the integration of our businesses in order to realign operations, reduce costs, achieve operational efficiencies and shift resources into geographic regions and end markets that are more consistent with our growth strategy. During the six months ended June 29, 2014, we paid $3.6 million related to these plans and recorded an additional charge of $0.1 million related to higher than expected costs associated with workforce reductions within our Human Health Segment. As of June 29, 2014, we had $9.7 million of remaining liabilities associated with these restructuring and integration plans, primarily for residual lease obligations related to closed facilities and remaining severance payments for workforce reductions in both our Human Health and Environmental Health segments. We expect to make payments for these leases, the terms of which vary in length, through fiscal year 2022. We anticipate the remaining severance payments for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2014, as local law requires some severance to be paid in monthly installments through the fourth quarter of fiscal year 2014.

Contract Termination Charges
We have terminated various contractual commitments in connection with certain disposal activities and have recorded charges, to the extent applicable, for the costs of terminating these contracts before the end of their terms and the costs that will continue to be incurred for the remaining terms without economic benefit to us. We recorded an additional pre-tax charge of $1.5 million, primarily as a result of terminating various contractual commitments in our Environmental Health segment, and we made payments for these obligations of $1.2 million in the first six months of fiscal year 2014. The remaining balance of these accruals as of June 29, 2014 was $0.6 million.

Interest and Other Expense, Net
Interest and other expense, net, consisted of the following:
 
Three Months Ended
 
Six Months Ended
 
June 29,
2014
 
June 30,
2013
 
June 29,
2014
 
June 30,
2013
 
(In thousands)
Interest income
$
(151
)
 
$
(64
)
 
$
(245
)
 
$
(169
)
Interest expense
9,079

 
11,913

 
18,298

 
23,606

Other expense, net
36

 
1,016

 
2,200

 
1,468

Total interest and other expense, net
$
8,964

 
$
12,865

 
$
20,253

 
$
24,905

Interest and other expense, net, for the three months ended June 29, 2014 was an expense of $9.0 million, as compared to an expense of $12.9 million for the three months ended June 30, 2013, a decrease of $3.9 million. The decrease in interest and other expense, net, for the three months ended June 29, 2014, as compared to the three months ended June 30, 2013, was primarily due to decreases in interest expense and other expense, net. Interest expense decreased by $2.8 million for the three months ended June 29, 2014, as compared to the three months ended June 30, 2013, primarily due to an increased mix of variable rate debt with lower interest rates. Other expense, net decreased by $1.0 million for the three months ended June 29, 2014, as compared to the three months ended June 30, 2013, and consisted primarily of expenses related to foreign currency transactions and foreign currency translation.
Interest and other expense, net, for the six months ended June 29, 2014 was an expense of $20.3 million, as compared to an expense of $24.9 million for the six months ended June 30, 2013, a decrease of $4.7 million. The decrease<